Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Mycobacterium tuberculosis and the response of its host
-
2. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
3. Immune response and rational development of vaccines and biomarkers
- Prof. Dr. Stefan H. E. Kaufmann
-
4. Molecular mechanisms of drug resistance in M. tuberculosis
- Dr. Daniela Cirillo
- The epidemiology of tuberculosis
-
5. The basic epidemiology of tuberculosis (TB)
- Dr. David Dowdy
-
6. Global epidemiology of TB
- Dr. Philippe Glaziou
-
7. Social determinants of tuberculosis
- Dr. Knut Lönnroth
- The control of tuberculosis
-
8. Treatment of tuberculosis
- Dr. Jean-Pierre Zellweger
-
9. The End TB Strategy towards TB elimination 1
- Dr. Mario Raviglione
-
10. The End TB Strategy towards TB elimination 2
- Dr. Mario Raviglione
-
11. Financing TB care and control
- Dr. Christopher Fitzpatrick
- Dr. Andrea Pantoja
-
12. Tuberculosis and COVID-19
- Prof. Giovanni Battista Migliori
-
13. Multidrug resistant tuberculosis (MDR-TB): an update
- Dr. Simon Tiberi
-
14. Impact of HIV on tuberculosis in the developing world and how to manage it
- Prof. Anthony D. Harries
-
16. TB in children
- Prof. Ben J. Marais
-
17. Community engagement in tuberculosis care
- Ms. Lana Syed
-
18. India: the epicentre of global TB control
- Dr. Madhukar Pai
-
19. Community engagement in TB care
- Dr. Haileyesus Getahun
- Research and development for new approaches in the control of tuberculosis
-
20. Development of new regimens for tuberculosis
- Dr. Zhenkun Ma
-
22. Pharmacometrics in tuberculosis
- Prof. Charles A. Peloquin
-
23. Extrapulmonary tuberculosis
- Dr. Scott Heysell
-
24. The role of surgery in tuberculosis management
- Dr. Richard Zaleskis
- Archived Lectures *These may not cover the latest advances in the field
-
25. The development of current treatments for tuberculosis
- Dr. Andrew Nunn
-
26. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
27. Basics of tuberculosis epidemiology
- Prof. Frank Cobelens
-
29. The international approach to the control of tuberculosis
- Dr. Mario Raviglione
-
30. Public-private mix for TB care and control
- Dr. Mukund Uplekar
Printable Handouts
Navigable Slide Index
- Introduction
- What is public-private mix?
- Fewer people accessed life-saving TB care in 2020
- Reaching all children and adolescents
- Drug resistant TB remains a public health crisis
- Global progress in provision of TB preventative treatment lags behind
- Private healthcare dominates in many high burden countries
- Contribution of public-private mix to TB case notifications
- Impact and implications of the COVID-19 pandemic on the TB response and PPM
- Opportunities for action
- Getting on track to reach UNHLM targets
- Strengthening M&E and accountability in PPM
- How do we scale up efforts on PPM?
- PPM roadmap (1)
- PPM roadmap (2)
- PPM roadmap (3)
- PPM roadmap (4)
- PPM roadmap (5)
- Timeline and targets
- Using the roadmap to drive action to End TB
- Thank you for your attention
Topics Covered
- Public-private mix (PPM)
- The impact of Covid-19 on the access to services
- PPM can reduce the burden of drug-resistant TB
- Global provision of TB preventative treatment
- Opportunities for action
- Monitoring, evaluation, and accountability in PPM
- Private health care providers in TB care and prevention
- PPM roadmap
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Dias, H.M. (2022, May 31). Reaching the missing millions through public-private mix (PPM) for TB prevention and care [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/WJVX7040.Export Citation (RIS)
Publication History
Financial Disclosures
- Ms. Hannah Monica Dias has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Reaching the missing millions through public-private mix (PPM) for TB prevention and care
Published on May 31, 2022
33 min
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Greetings.
This is Hannah Monica Dias from
the World Health Organization
Global Tuberculosis Program.
I lead the work at WHO
on reaching the
millions of people with
TB prevention and care
through the flagship initiative,
Find, Treat All, End TB,
through efforts on
public-private mix or
or public-private
partnerships which help
strengthen engagement
with all care providers,
this is the topic
for the talk today.
I also lead the work
on TB elimination.
0:42
The main focus of this talk
is to reach the missing
millions of people
who don't access TB
prevention or care services,
or they miss out on accessing
lifesaving TB prevention
and care services.
One of the core approaches to
achieving this is called
public-private mix (PPM).
Public-private mix
is a key component
of WHO's End TB strategy.
We've had policies
spanning decades on this,
but it's only recently
that we've seen that
public-private mix is being
slowly-scaled up by countries.
What does PPM really mean?
PPM, or public-private mix,
encompasses diverse
collaborative strategies.
It refers to public-public mix,
which basically
means engagement by
the national TB program of
public sector care providers
that are not directly linked
to national TB programs.
This can be public hospitals
like in Indonesia,
public medical colleges
like in India,
prisons or detention centers,
military facilities, railways,
public health insurance
organizations
like in a lot of Latin America.
Often, these unengaged
public sector care providers
manage a lot of people with TB,
but they don't necessarily
report them to
national programs
and so we don't
know what kind of care
they're receiving,
or if the right guidelines
are being followed.
It's really important
to make sure that
public sector comprehensive
engagement is achieved,
especially if you know
from an analysis of
the patient pathway in countries
that the public unengaged
care providers are
actually a part of a
big provision of care
for people with TB,
so it's really important
to engage with them.
The second strategy is
public-private mix,
and this refers to
the engagement by
the national TB program of
private sector care providers,
especially in countries
with a large private sector
and this can include
private individual
and institutional providers,
the corporate or business
sector, mission hospitals,
nongovernmental organizations
and faith-based organizations.
In a nutshell, we
are looking both at
public-public mix and
public-private mix
to make sure that all
care providers are
engaged in efforts to end TB.
Hide